Physician profile
Raymond Turnure
NPI 1639157423
$4,289.77
in general payments reported to CMS, 2019-2025
31 companies · $50.20 in 2025
The $50.20 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $888 · 2021: $974 · 2022: $706 · 2023: $781 · 2024: $318 · 2025: $50.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.43 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,354.23 | 2021-2025 | Qulipta, Botox, Vraylar |
| Allergan, INC. | $850.69 | 2019-2022 | |
| Novo Nordisk INC | $282.85 | 2019-2024 | Wegovy |
| Amgen INC. | $219.82 | 2019-2024 | Repatha, Prolia, Evenity |
| Glaxosmithkline, LLC. | $212.73 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $137.95 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $123.91 | 2019-2020 | |
| Pfizer INC. | $115.14 | 2019-2023 | |
| Lilly USA, LLC | $106.32 | 2019-2024 | Zepbound, Jardiance |
| Astellas Pharma US INC | $96.73 | 2023 | Veozah |
| Amarin Pharma, INC. | $95.17 | 2019-2021 | |
| Kaleo, INC. | $92.01 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $87.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $62.06 | 2022-2023 | Breztri |
| Merz Pharmaceuticals, LLC | $46.05 | 2023 | Xeomin |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.80 | 2019 | |
| Sanofi Pasteur INC. | $37.78 | 2019-2020 | |
| Merz North America, INC. | $31.99 | 2025 | |
| Idorsia Pharmaceuticals US INC | $30.42 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $29.03 | 2019-2020 | |
| Eisai INC. | $26.61 | 2020 | |
| Kyowa Kirin, INC. | $25.93 | 2023 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $24.49 | 2021 | |
| Boston Scientific Corporation | $24.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.24 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.83 | 2021 | |
| Exact Sciences Corporation | $17.35 | 2023 | Cologuard Collection Kit |
| Si-Bone, INC. | $16.36 | 2019 | |
| Merck Sharp & Dohme LLC | $16.25 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.11 | 2023 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Turnure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.